Scorpion venom is a highly complex mixture of about 100–700 different components, where peptides are the major constituents with various biological and pharmacological properties including anticancer activities. In this study, anticancer efficacy of the venom of the Egyptian scorpion Androctonus amoreuxi has been evaluated. In vitro, the human breast cancer MCF-7 cell line was treated with the venom and the IC50 was estimated. In vivo studies, Ehrlich ascites carcinoma (EAC) cells were inoculated into CD-1 mice intraperitoneally to form liquid tumor or subcutaneously to form solid tumor and then treated with intraperitoneal injection with venom (0.22 mg/kg) every other day. The total tumor cells in the ascitic fluid and the size of the solid tumor were assessed after 14 and 30 days, respectively. In addition, the mean survival time (MST), body weight, tumor volume, PCV, viability of tumor cells, CBC, AST, ALP, creatinine, oxidative stress biomarkers (GSH, MDA, PCC), tumor marker Ki67, growth factor VEGF and caspase-3 were measured in normal control, EAC control and venom-treated groups (n = 6). Treatment with venom induced anti-tumor effects against liquid and in solid tumors as indicated by a significant (P < 0.05) reduction in tumor volume/size, count of viable EAC cells, expression of Ki67 and VEGF as well as by remarkable increases in MST and caspase-3 expression as compared to non-treated group. Interestingly, the venom restored the altered hematological and biochemical parameters of tumor-bearing animals and significantly increased their life span. These data indicate to (1) the cytotoxic potential effects of A. amoreuxi on tumor cells via anti-proliferative, apoptotic and anti-angiogenic activities; (2) opening a new avenue for further studies on the anti-cancer effects of this agent.

No abstract

Background Scorpion venom is a very complicated mixture of various peptides/proteins which could induce toxicological and pharmacological responses. This investigation was conducted to evaluate the possible pharmacological properties (analgesic, antipyretic, and antiinflammatory effects) of the Egyptian scorpion venom Androctonus amoreuxi in mice and rats injected intraperitoneally with 1/10 and 1/5 LD50 (0.11 and 0.22 mg/kg for mice; 0.385 and 0.77 mg/kg for rats, respectively). Results The peripheral and central analgesic effect of A. amoreuxi venom was determined using the tests of mice-abdominal writhing and tail immersion of rats, respectively. The antipyretic and antiinflammatory activities were examined using the pyrexia rats model induced by Brewer’s yeast and the paw mice edema induced by carrageenan, respectively. The venom of A. amoreuxi produced significant (p < 0.05) peripheral and central analgesic activity in both animal models. Also, treatment with the scorpion venom showed significant (p < 0.05) dose-independent reduction in pyrexia of rats. More importantly, the venom significantly inhibited mice paw edema induced by carrageenan. Conclusion Accordingly, the present results showed that the venom of this scorpion possesses remarkable pharmacological properties (analgesic, antipyretic, and antiinflammatory activities) on animal models, and might be contain certain peptides responsible for the reported activities.